Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Merck/Schering-Plough pipeline

Merck/Schering-Plough pipeline

By acquiring Schering-Plough(NYSE:SGP), Merck (NYSE:MRK) will nearly double the number of Phase III compounds it

Read the full 168 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE